Prof. Dr. med. Matthias Lüke, FEBO

1997-2004   Studium der Humanmedizin an der Universität zu Köln

2005    Promotion

2010    Anerkennung als Facharzt für Augenheilkunde und Oberarzt an der Klinik für Augenheilkunde des Universitätsklinikums Schleswig-Holstein Campus Lübeck

2016    Verleihung des Titels „Außerplanmäßiger Professor“ der Universität zu Lübeck durch den Präsidenten Herrn Universitätsprofessor Dr. med. Dr. h.c. Hendrik Lehnert

2017    Vergabe der Zusatzbezeichnung „Fellow of the European Board of Ophthalmology“(FEBO) durch die Europäische Fachgesellschaft für Augenheilkunde

2005    Arzt und wissenschaftlicher Mitarbeiter an der Universitätsaugenklinik Tübingen

2008    Wechsel an die Klinik für Augenheilkunde des Universitätsklinikums Schleswig-Holstein Campus Lübeck

2008    Beginn der operativen Ausbildung im Rahmen der universitären Maximalversorgung für die konservative und chirurgische Therapie des gesamten Spektrums der Erkrankungen der vorderen und hinteren Augenabschnitte einschließlich der Katarakt-, Glaukom-, Hornhaut-, Netzhaut- und Traumachirurgie

2012    Stellvertretender geschäftsführender Direktor und Personaloberarzt der Klinik für Augenheilkunde des Universitätsklinikums Schleswig-Holstein Campus Lübeck

2017-2021   Niederlassung in der Praxis „Augenheilkunde am Rheincenter“ in Köln

• Lehrtätigkeit an der Universität zu Lübeck im Rahmen der Hauptvorlesung:
• „Makulaerkrankungen“ und Blockseminare zu unterschiedlichen Themen
• Betreuung von Studenten der Humanmedizin an der Universität Tübingen und Lübeck
• Betreuung von Promotionsstudenten an der Universität Tübingen und Lübeck

• Deutsche ophthalmologische Gesellschaft (DOG)
• Retinologische Gesellschaft
• BDOC (Bund deutscher Ophthalmochiurgen)
• BVA (Berufsverband der Augenärzte Deuschlands e.V.)
• Club Jule Gonin

Orginalarbeiten

Mohi A , Gniesmer S , Ranjbar M , Kakkassery V, Grisanti S, Neppert B, Kurz M, Lüke J , Lüke M, Müller M , Lommatzsch C, Grisanti S (2021) Ophthalmologe 118(7):652-658. Digital teaching 2020: students assess attention during an online lecture as equivalent to a face-to-face lecture, IF: 1,059.

Ranjbar M, Schneider T, Brand C, Grisanti S, Lüke J, Lüke M (2017) J Curr Ophthalmol. 2017 Jan 12;29(1):69-71The effect of anakinra on retinal function in isolated perfused vertebrate retina. IF: 1,42.

Mohi A , Gniesmer S , Ranjbar M , Kakkassery V, Grisanti S, Neppert B, Kurz M, Lüke J , Lüke M, Müller M , Lommatzsch C, Grisanti S (2021) Ophthalmologe 118(7):652-658. Digital teaching 2020: students assess attention during an online lecture as equivalent to a face-to-face lecture, IF: 1,059.

Ranjbar M, Schneider T, Brand C, Grisanti S, Lüke J, Lüke M (2017) J Curr Ophthalmol. 2017 Jan 12;29(1):69-71The effect of anakinra on retinal function in isolated perfused vertebrate retina. IF: 1,42.

Vukoja V, Brandenbusch T, Tura A, Nassar K, Rohrbach DJ, Lüke M, Grisanti S, Lüke J. (2016) Expression of EphA2 in Metastatic and Non-Metastatic Primary Uveal MelanomaKlin Monbl Augenheilkd. 2016 Feb 8. [im Druck], IF 0,459

Stenzel M, Tura A, Nassar K, Rohrbach JM, Grisanti S, Lüke M, Lüke J (2016) Analysis of Caveolin-1 and Phosphoinositol-3 Kinase expression in primary uveal melanomas. Clin Experiment Ophthalmol., [im Druck], IF 2.347

Mazinani B, Baumgarten S, Schiller P, Agostini H, Helbig H, Limburg E, Hellmich M, Walter P; VIPER Study Group. (2016) Vitrectomy with or without encircling band for pseudophakic retinal detachment: a multi-centre, three-arm, randomised clinical trial. VIPER Study Report No. 1-design and enrolment. Br J Ophthalmol., Br J Ophthalmol.100(3):405-10. IF 2,976

Siapich SA, Akhtar I, Hescheler J, Schneider T, Lüke M. (2015) Low concentrations of ethanol but not of dimethyl sulfoxide (DMSO) impair reciprocal retinal signal transduction. Graefes Arch Clin Exp Ophthalmol 253:1713-9, IF 1,908

Grisanti S, Zhu Q, Tatar O, Lüke J, Lüke M, Tura A, Grisanti S. (2015) Differential expression of vascular endothelial growth factor-a isoforms in neovascular age-related macular degeneration. Retina 35: 764-72, IF 3,243.

Ranjbar M, Schneider T, Brand C, Grisanti S, Lüke J, Lüke M. (2015) The Effect of Disease-Modifying Antirheumatic Drugs on Retinal Function in the Electrophysiological ex vivo Model of the Isolated Perfused Vertebrate Retina. Ophthalmic Res 53: 136-140, IF 1,422.

Nassar K, Lüke J, Lüke M, Kamal M, Soliman MM, Grisanti S, Grisanti S. (2015) Effect of different fixative solutions on eyes with experimental proliferative vitreoretinopathy. Int J Exp Pathol 96: 103-10, IF 2,168.

Nassar K, Tura A, Lüke J, Lüke M, Soliman M, Grisanti S, Grisanti S. (2015) A p38 MAPK Inhibitor Improves Outcome after Glaucoma Filtration Surgery. J Glaucoma 24: 165-78, IF 2,106.

Nassar K, Grisanti S, Elfar E, Lüke J, Lüke M, Grisanti S. (2015) Serum cytokines as biomarkers for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 253: 699-704, IF 1,908.

Tura A, Alt A, Haritoglou C, Meyer CH, Schneider T, Grisanti S, Lüke J, Lüke M; for the International Chromovitrectomy Collaboration. (2014) Testing the effects of the dye Acid violet-17 on retinal function for an intraocular application in vitreo-retinal surgery. Graefes Arch Clin Exp Ophthalmol. Graefes Arch Clin Exp Ophthalmol 252: 1927-37, IF 1,908.

Tura A, Lüke J, Merz H, Reinsberg M, Lüke M, Jager MJ, Grisanti S. (2014) Identification of circulating melanoma cells in uveal melanoma patients by dual-marker immunoenrichment. Invest Ophthalmol Vis Sci 55: 4395-404, IF 3,404.

Nassar K, Grisanti S, Tura A, Lüke J, Lüke M, Soliman M, Grisanti S.(2014) A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy. Exp Eye Res 123: 72-86, IF 2,709.

Ranjbar M, Alt A, Nassar K, Reinsberg M, Schneider T, Grisanti S, Lüke J, Lüke M. (2014) The concentration-dependent effects of indocyanine green on retinal function in the electrophysiological ex vivo model of isolated perfused vertebrate retina. Ophthalmic Res 51: 167-71, IF 1,422.

Januschowski K, Schnichels S, Hagemann U, Koch V, Hofmann J, Spitzer MS, Bartz-Schmidt KU, Szurman P, Lüke M, Aisenbrey S. (2014) Electrophysiological toxicity testing of VEGF Trap-Eye in an isolated perfused vertebrate retina organ culture model. Acta Ophthalmol 92: e305-11, IF 2,844.

Alt A, Hilgers RD, Tura A, Nassar K, Schneider T, Hueber A, Januschowski K, Grisanti S, Lüke J, Lüke M. (2013) The neuroprotective potential of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in response to hypoxia in isolated bovine retina. Cell Physiol Biochem 32: 218-34, IF 2,875.

Lüke J, Nassar K, Lüke M, Grisanti S. (2013) Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma–results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol 251: 2403-13, IF 1,908.

Lüke J, Lüdeke I, Acksteiner A, Nassar K, Hoerauf H, Grisanti S, Lüke M. (2013) Morphological and functional outcome after brilliant blue G-assisted macular hole surgery. Ophthalmologica 230: 81-6, IF 1,676.

Rassaei M, Thelen M, Abumuaileq R, Hescheler J, Lüke M, Schneider T. (2012) Effect of high-intensity irradiation from dental photopolymerization on the isolated and superfused vertebrate retina. Graefes Arch Clin Exp Ophthalmol 3: 751-62, IF 1,908.

Januschowski K, Maddani R, Mueller S, Lüke M, Spitzer MS, Schultheiss M, Bartz-Schmidt KU, Szuman P (2012) Comparing the effects of two different irrigation solutions on an isolated perfused vertebrate retina. Ophthalmic Res 48: 59-66, IF 1,422.

Alnawaiseh M, Albanna W, Chen CC, Campbell KP, Hescheler J, Lüke M, Schneider T (2011) Two separate Ni(2+) – sensitve voltage-gated Ca(2+) channels modulate transretinal signalling in the isolated murine retina. Acta Ophthalmol 89: 579-90, IF 2,844.

Nassar K, Lüke J, Lüke M, Kamal M, Abd El-Nabi E, Soliman M, Rohrbach M, Grisanti S (2011) The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefes Arch Clin Exp Ophthalmol 249: 1649-60, IF 1,908.

Radhakrishnan K, Kamp MA, Siapich SA, Hescheler J, Lüke M, Schneider T (2011) Ca(v)2.3 Ca channel interacts with the G1-subunit of V-ATPase. Cell Physiol Biochem 27: 421-32, IF 2,875.

Lüke J, Wegner J, Wegner R, Nassar K, Tatar O, Rohrbach JM, Hilgers RD, Lüke M, Grisanti S. (2011) Expression of c-Kit and its ligand SCF in primary uveal melanoma.  Eur J Ophthalmol 21(5): 615-24, IF 1,068.

Januschowski K, Mueller S, Spitzer MS, Lüke M, Bartz-Schmidt KU, Szurman P. (2011) The effects of the intraocular dye brilliant blue G (BBG) mixed with varying concentrations of glucose on retinal function in an isolated perfused vertebrate retina. Graefes Arch Clin Exp Ophthalmol 249: 483-9, IF 1,908.

Lüke J, Nassar K, Lüke M, Tura A, Merz H, Giannis A, Grisanti S. (2010) The effect of adjuvant dimethylenastron, a mitotic Kinesin Eg5 inhibitor, in experimental glaucoma filtration surgery. Curr Eye Res 35(12): 1090-8, IF 1,639.

Siapich SA, Wrubel H, Albanna W, Alnawaiseh M, Hescheler J, Weiergräber M, Lüke M, Schneider T (2010) Effect of ZnCl2 and chelation of zinc ions by N.N-diethyldithiocarbamate (DEDTC) on the ERG b-wave amplitude from the isolated superfused vertebrate retina. Curr Eye Res 35: 322-24, IF 1,639.

Lüke M, Januschowski K, Lüke J, Grisanti S, Szurman P, Dietz K, Kampik A, Bartz-Schmidt KU, Eibl-Lindner KH (2010) The safety profile of alkylphosphocholines in the model of the isolated perfused vertebrate retina. Graefes Arch Clin Exp Ophthalmol 248: 511-8, IF 1,908.

Lüke M, Januschowski K, Tura A, Lüke J, Nassar K, Lüke C, Schneider T, Bartz-Schmidt KU, Grisanti S, Szurman P (2010) The effects of pegaptanib sodium on retinal function in isolated perfused vertebrate retina. Curr Eye Res 35: 248-54, IF 1,639.

Lüke J, Tatar O, Lüke M, Bartz-Schmidt KU, Grisanti S (2010) Papillary capillary activation in Terson syndrome. Int Ophthalmol 30: 439-441, IF 0,705.

Beutel J, Peters S, Lüke M, Aisenbrey S, Szurman P, Spitzer MS, Yoeruek E; the Bevacizumab Study Group, Grisanti S (2010) Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol 88(1): 103-9, IF 2,844.

Beutel J, Ziemssen F, Lüke M, Partsch M, Bartz-Schmidt KU; The Bevacizumab Study Group, Gelisken F (2010) Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results. Int Ophthalmol 30(1):15-22, IF 0,705.

Beutel J, Wegner J, Wegner R, Ziemssen F, Nassar K, Rohrbach JM, Hilgers RD, Lüke M, Grisanti S (2009) Possible implications of MCAM expression in metastasis and non-metastatic of primary uveal melanoma patients.  Curr Eye Res 34: 1004-9, IF 1,639.

Albanna W, Banat M, Albanna N, Alnawaiseh M, Siapich SA, Igelmund P, Weiergräber M, Lüke M, Schneider T (2009) Longer lasting electroretinographic recordings from the isolated and superfused murine retina. Graefes Arch Clin Exp Ophthalmol 247(10): 1339-52, IF 1,908.

Beutel J, Lüke M, Bartz-Schmidt KU, Grisanti S (2009) Vitreal induzierte RPE-Zell-Traktion – Untersuchung pathologischer Glaskörperproben in einem In-vitro-Kontraktionsmodell. Ophthalmologe 106(10): 893-8, IF 0,504.

Lüke M, Januschowski K, Lüke J, Peters S, Wirtz N, Yörük E, Lüke C, Bartz-Schmidt KU, Grisanti S, Szurman P (2009) The effects of ranibizumab (Lucentis®) on retinal function in isolated perfused vertebrate retina. Br J Ophthalmol 93(10): 1396-400, IF 2,976.

Lüke M, Ziemssen F, Völker M, Altpeter E, Beutel J, Besch D, Bartz-Schmidt KU, Gelisken F (2009) Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol 247(6): 745-54, IF 1,908.

Peters S, Tatar O, Spitzer MS, Szurman P, Aisenbrey S, Lüke M, Adam A, Yoeruek E, Grisanti S (2009) Analysis of the neuronal marker protein gene product 9.5 in internal limiting membranes after indocyanine-green assisted peeling. Retina 29(2): 243-7, IF 3,243.

Siapich SA, Banat M, Albanna W, Hescheler J, Lüke M, Schneider T (2009) Antagonists of ionotropic GABA-receptors impair the NiCl2 mediated stimulation of the ERG b-wave amplitude from the isolated superfused vertebrate retina. Acta Ophthalmol 87 (8): 854-65, IF 2,844.

Banat M, Lüke M, Siapich SA, Hescheler J, Weiergräber M, Schneider T (2008) The dihydropyridine isradipine inhibits the murine but not the bovine A-wave response of the electroretinogram. Acta Ophthalmol 86(6): 676-82, IF 2,844.

Lüke C, Dietlein TS, Lüke M, Konen W, Krieglstein GK (2008) A prospective trial of phaco-trabeculotomy combined with deep sclerectomy versus phaco-trabeculectomy. Graefes Arch Clin Exp Ophthalmol 246(8): 1163-8, IF 1,908.

Lüke M, Januschowski K, Beutel J, Lüke C, Grisanti S, Peters S, Jaissle GB, Bartz-Schmidt KU, Szurman P (2008) Electrophysiological effects of Brilliant Blue G in the model of the isolated perfused vertebrate retina. Graefes Arch Clin Exp Ophthalmol 246(6): 817-22, IF 1,908.

Lüke M, Januschowski K, Warga M, Beutel J, Grisanti S, Peters S, Schneider T, Lüke C, Bartz-Schmidt KU, Szurman P (2008) The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res 87(1): 22-9. IF 2,709.

Ulmer A, Beutel J, Süsskind D, Hilgers RD, Ziemssen F, Lüke M, Röcken M, Rohrbach M, Fierlbeck G, Bartz-Schmidt KU, Grisanti S (2008) Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res 14(14): 4469-74, IF 8,722.

Yoeruek E, Spitzer MS, Tatar O, Biedermann T, Grisanti S, Lüke M, Bartz-Schmidt KU, Szurman P (2008) Toxic effects of recombinant tissue plasminogen activator on cultured human corneal endothelial cells. Invest Ophthalmol Vis Sci 49(4): 1392-7, IF 3,404.

Ziemssen F, Lüke M, Bartz-Schmidt KU, Gelisken F (2008) Time-dependent effects on contrast sensitivity, near and distance acuity: difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation). Graefes Arch Clin Exp Ophthalmol 246(5): 653-9, IF 1,908.

Ziemssen F, Lüke M, Messias A, Beutel J, Tatar O, Zrenner E, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group (2008) Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 28(2): 101-9, IF 0,705.

Beutel J, Greulich L, Lüke M, Ziemssen F, Szurman P, Bartz-Schmidt KU, Grisanti S (2007) Inner limiting membrane as membranous support in RPE sheet-transplantation. Graefes Arch Clin Exp Ophthalmol 245(10): 1469-73, IF 1,908.

Lüke C, Dietlein TS, Lüke M, Konen W, Krieglstein GK (2007) The complication profile of Phaco-Trabeculotomy combined with deep Sclerectomy – a new technique in combined cataract and glaucoma surgery. Acta Ophthalmol 85(2): 143-8, IF 2,844.

Lüke C, Lüke M, Aisenbrey S, Bartz-Schmidt KU, Walter P, Kirchhof B (2007) Effekte der 360°-Retinotomie und Makulatranslokation auf das skotopische Dreichfachblitz-ERG bei Patienten mit exsudativer altersbedingter Makuladegeneration. Klin Monatsbl Augenheilkd 224(12): 120-6, IF 0,459.

Lüke M, Januschowski K, Warga M, Beutel J, Leitritz M, Gelisken F, Grisanti S, Schneider T, Lüke C, Bartz-Schmidt KU, Szurman P (2007) The retinal tolerance to bevacizumab in coapplication with a recombinant tissue plasminogen activator. Br J Ophthalmol 91(8): 1077-82, IF 2,976.

Lüke M, Krott R, Warga M, Szurman P, Grisanti S, Bartz-Schmidt KU, Schneider T, Lüke C (2007) Effects of the Protein Tyrosine Kinase Inhibitor Genistein and Taurine on Retinal Function in Isolated Superfused Retina. Graefes Arch Clin Exp Ophthalmol 245(2): 242-8, IF 1,908.

Lüke M, Szurman P, Schneider T, Lüke C (2007) The effects of the Phosphodiesterase Type V Inhibitor Sildenafil on human and bovine retinal function in vitro. Graefes Arch Clin Exp Ophthalmol 245(8): 1211-5, IF 1,908.

Lüke M, Ziemssen F, Lüke C , Bartz-Schmidt KU, Gelisken F (2007) Quality of life in a prospective randomized study of PDT vs Macular Translocation with 360° Retinotomy for Neovascular Age-related Macular Degeneration. Graefes Arch Clin Exp Ophthalmol 245(12): 1831-6, IF 1,908.

Peters S, Altvater A, Bopp S, Vonthein R, Szurman P, Spitzer MS, Warga M, Lüke M, Bartz-Schmidt KU, Grisanti S (2007) Systematic evaluation of ICG and trypan blue related effects on ARPE-19 cells in vitro. Exp Eye Res 85(6): 880-9, IF 2,709.

Szurman P, Kaczmarek R, Jaissle GB, Grisanti S, Lüke M, Spitzer MS, Heide PE, Bartz-Schmidt KU (2007) Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol 245(5): 689-96, IF 1,908.

Szurman P, Sierra A, Kaczmarek R, Jaissle GB, Wallenfels-Thilo B, Grisanti S, Lüke M, Bartz-Schmidt KU, Spitzer MS (2007) Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo. Exp Eye Res 85(1): 44-53, IF 2,709.

Yoeruek E, Jaegle H, Lüke M, Grisanti S, Warga M, Krott R, Spitzer MS, Bartz-Schmidt KU, Szurman P (2007) Safety profile of a taurine containing irrigation solution (AcriPurRet®) in pars plana vitrectomy. Retina 27(9): 1286-91, IF 3,243.

Lüke C, Lüke M, Sickel W, Schneider T (2006) Effects of patent blue on human retinal function.  Graefes Arch Clin Exp Ophthalmol 244(9): 1188-90, IF 1,908.

Lüke M, Warga M, Lüke C, Ziemssen F, Gelisken F, Grisanti S, Bartz-Schmidt KU, Szurman P (2006) The Effects of Bevacizumab (Avastin, Genentech) on the isolated superfused vertebrate retina. Br J Ophthalmol 90(9): 1178-82, IF 2,976.

Szurman P, Roters S, Grisanti S, Aisenbrey S, Schraermeyer U, Lüke M, Bartz-Schmidt KU, Thumann G (2006) Ultrastructural changes after artificial retinal detachment with modified retinal adhesion. Invest Ophthalmol Vis Sci 47(11): 4983-9, IF 3,404.

Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Lüke M, Bartz-Schmidt KU, Grisanti S (2006) Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 142(1): 95-104, IF 3,871.

Hueber A, Lüke M, Esser PJ, Kirchhof B, Sickel W, Lüke C (2005) Effects of daunorubicin and CD95L on retinal function in superfused vertebrate retina. J Ocul Pharmacol Ther 21(2): 133-8, IF 1,470.

Lüke M, Henry M, Lingohr T, Maghsoodian M, Hescheler J, Weiergräber M, Sickel W, Schneider T  (2005) A Ni(2+)-sensitive component of the ERG b-wave from the isolated bovine retina is related to E-type voltage-gated Ca(2+) channels. Graefes Arch Clin Exp Ophthalmol 243(9): 933-41, IF 1,908.

Lüke M, Lüke C, Hescheler J, Schneider T, Sickel W (2005) Effects of  phosphodiesterase type 5 inhibitor sildenafil on retinal function in isolated superfused retina. J Ocul Pharmacol Ther 21(4): 305-14, IF 1,470.

Lüke C, Lüke M, Dietlein TS, Hueber A, Jordan J, Sickel W, Kirchhof B (2005) Retinal tolerance to dyes. Br J Ophthalmol 89(9): 1188-91, IF 2,976.

Lüke M, Weiergräber M, Brand C, Siapich SA, Hescheler J, Lüke C, Schneider T (2005) The isolated perfused bovine retina – a sensitive tool for pharmacological research on retinal function. Brain Res Brain Res Protoc 16(1-3): 27-36, IF 1,818.

Lüke C, Alteheld N, Aisenbrey S, Lüke M, Bartz-Schmidt KU, Walter P, Kirchhof B (2003) Electro-oculographic findings after 360 degrees retinotomy and macular translocation for subfoveal choroidal neovascularisation in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 241(9): 710-5, IF 1,908.

Lüke C, Aisenbrey S, Lüke M, Marzella G, Bartz-Schmidt KU, Walter P (2001) Electrophysiological changes after 360 degrees retinotomy and macular translocation for subfoveal choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol 85: 928-932, IF 2,976.

Lüke C, Krott R, Lüke M, Lebek J, Walter P, Brunner R, Sickel W (2001) Effects of protein tyrosine kinase inhibitor genistein on retinal function in superperfused vertebrate retina. J Ocul Pharmacol Ther 17: 151-158, IF 1,470.

 

Übersichtsarbeiten

Lüke M, Lüke J (2021) Lasertherapie oder IVOM beim Neovaskularisationsglaukom? Der Augenspiegel 05/2021, IF: 0,1.

Grisanti S, Lüke J, Lüke M, Rudolf M, Peters S (2014) Current and future strategies for nonexudative age-related macular degeneration. Expert Review of Ophthalmology 01/2014; 6(3), IF 0,2.

Lüke J, Tura A, Lüke M, Grisanti S (2013) Zirkulierende Tumorzellen bei uvealen Melanomen – ein neues diagnostisches Tool. Der Augenspiegel 03: 34-37, IF 0,2.

Lüke M (2011) Okuläre Gefässverschlüsse. Spiegel einer Systemerkrankung. Augenspiegel 01: 22-25, IF 0,2.

Lüke J, Lüke M, Grisanti S (2009) Antiangiogene Therapie bei neovaskulärem Glaukom und nach Filterkissenchirurgie. Ophthalmologe 106(5):407-12, IF 0,504.
Lüke M (2009) Die intravitreale Therapie – Freud oder Leid der Netzhaut. Z prakt Augenheilkd DOG-Kongress-Spezial: 386-390, IF 0,2.

Rohrbach JM, Neuhann I, Lüke M, Aisenbrey S (2007) Tödlicher Unfall oder Kindesmißhandlung mit Todesfolge: Die Netzhaut als „letzter Zeuge“. Z prakt Augenheilkd 28: 440-450, IF 0,2.

 

Fallberichte

Lüdeke I, Terheyden P, Grisanti S, Lüke M (2017) Entwicklung einer serösen Retinopathie unter Behandlung eines metastasierten kutanen Melanoms. Der Ophthalmologe IF 0,504.

Gemoll K, Lüdeke I, Lüke M (2013) Multiple bilateral gelegene Raumforderungen der Aderhaut. Der Ophthalmologe 114(4):378-380, IF 0,504.

Lüke J, Nassar K, Grisanti S, Lüke M (2013) Regression of rubeosis in the fellow eye after intravitreal ranibizumab injection. Graefes Arch Clin Exp Ophthalmol 251: 371-3, IF 1,908

Lüdeke I, Eggers J, Lüke M. (2011) „Letzte Wiese“ Sehnerv – Wie aus einem einfachen Niesen ein neurologischer Notfall wurde. Der Augenspiegel 12: 38-40, IF 0,2.

Wirtz N, Biester S, Weckerle P, Lüke M (2009) Anämie als Ursache einer beidseitigen Stauungspapille. Der Ophthalmologe 106(10): 928-31, IF 0,504.

Lüke C, Dohmen C, Dietlein TS, Brunner R, Lüke M, Krieglstein GK (2007) High-dose intravenous immunoglobulins for treatment of optic neuritis in Guillain-Barré syndrome. Klin Monatsbl Augenheilkd 224(12): 932-4, IF 0,459.

 

Buchbeiträge

Lüke J., Lüke M, Grisanti S (2015) Neovascular glaucoma In: Anti-Angiogenic Therapy in Ophthalmology“ (Andreas Stahl, ed), Springer, Essentials in Ophthalmology, pp 149-157

Lüke M, Grisanti S, Lüke J (2013) The retinal biocompatibility of dyes in the ex-vivo model of the isolated superfused vertebrate retina In: ‚Chromovitrectomy‘ edited by Carsten H. Meyer (Olten, Switzerland) Karger-Verlag Ophthalmologica. 230 Suppl 2:21-6.

Lüke M, Warga M, Beutel J, Szurman P (2008) Die Effekte von Bevacizumab und seiner Trägersubstanz auf die Funktion der isolierten und perfundierten Vertebratennetzhaut. In: Bartz-Schmidt KU, Ziemssen F (Hrsg) Intravitreale Pharmakotherapie – Moderne Medikamente und ihre Anwendung am Auge. Schattauer, pp 89-93

2008    Tierschutz-Forschungspreis zur Förderung von methodischen Arbeiten mit dem Ziel der Einschränkung und des Ersatzes von Tierversuchen verliehen durch das Bundesministerium für Ernährung, Landwirtschaft und Verbraucherschutz (BMELV)

2009    UniTransfer-Preis der Universität zu Lübeck

2010    DOC-Forschungpreis der Deutschen Ophthalomochirugen

2014    Travel Grant vergeben durch den Club Jules Gonin

2017    DOC-Medaille in Bronze für hervorragenden Leistungen und besondere Verdienste in der Augenchirurgie